GSK and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for JEMPERLI for the treatment of patients with recurrent or advanced dMMR/MSI-H endometrial cancer
MISSISSAUGA, ON - GSK is pleased to announce it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Jemperli (dostarlimab for injection) in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer. The negotiation concluded on October 11, 2024 with a letter of intent (LOI).
GSK is committed to ensuring timely public access to Jemperli for endometrial patients. We recognize the pCPA’s efforts and shared commitment to achieving this goal. This milestone underscores the need to expedite public reimbursement and as such, GSK looks forward to working with provincial and territorial governments and other stakeholders to make Jemperli available through public drug plans.
“We look forward to working with regional governments and stakeholders to see reimbursement in every province and territory so those living with endometrial cancer, particularly at an advanced stage, can access Jemperli,” said Sridhar Venkatesh, President & General Manager, GSK Canada. “We remain dedicated to advancing our immuno-oncology portfolio and developing new treatments for the benefit of Canadians with endometrial cancer and other types of solid tumours.”
“This announcement represents a critical step forward for endometrial cancer patients in Canada,” said Filomena Servidio-Italiano, President & CEO, Colorectal Cancer Resource & Action Network (CCRAN), a patient advocacy group dedicated to improving the longevity and quality of life for all cancer patients in Canada. “I applaud the efforts of GSK and the pCPA to make this treatment option available for Canadian patients through public reimbursement, which could have a positive impact in their cancer care.”
Jemperli in combination with carboplatin and paclitaxel was approved by Health Canada in 2023 as a treatment option for adult patients with primary advanced or recurrent dMMR/MSI-H endometrial cancer in patients who are candidates for systemic therapy.
About endometrial cancer
Endometrial cancer is found in the inner lining of the uterus, known as the endometrium. Endometrial cancer is one of the most common gynaecologic cancers in developed countries [i] with about 8,100 new cases of endometrial cancer diagnosed every year in Canada.[ii] Incidence rates are expected to rise by almost 40 per cent by 2040.[iii], [iv]
Approximately 15-20 per cent of patients with endometrial cancer will be diagnosed with advanced disease at the time of diagnosis.[v], [vi] An estimated 20-29 per cent of all endometrial cancers are dMMR/MSI-H.[vii] Chemotherapy has been the current standard of care for the majority of patients with primary advanced or recurrent endometrial cancer, and many patients eventually experience disease progression.[viii]
About Jemperli
Jemperli is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. In Canada, Jemperli (dostarlimab for injection) is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with primary advanced or recurrent mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer who are candidates for systemic therapy, and as monotherapy for the treatment of adult patients with dMMR or MSI-H recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum containing regimen. Jemperli has also been accepted for review by Health Canada for an expanded indication in primary advanced endometrial cancer.
Please consult the Product Monograph at www.gsk.ca for complete safety information. The Product Monograph is also available by calling 1-800-387-7374.
GSK in gynaecologic oncology
GSK is committed to maximizing patient survival through transformational medicines with a current effort on breakthroughs in oncology, including gynaecologic cancers, some of the most common cancers affecting women. We are focused on developing new medicines across a range of different modalities both as monotherapy and in combination for a variety of cancers, including ovarian and endometrial. We have a unique research and development approach, utilizing synthetic lethality and immuno-oncology to target specific proteins and biomarkers in ovarian cancer and endometrial cancer, enabling us to develop targeted treatments.
About GSK
We are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. Find out more at www.gsk.ca.
References
[i] Faizan U, Muppidi V. Uterine Cancer. [Updated 2022 Sep 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK562313/.
[ii] Lee, S. (n.d.). Canadian cancer statistics. Canadian Cancer Society. https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics.
[iii] Braun MM, et al. Am Fam Physician. 2016;93(6):468-474.
[iv] International Research on Cancer. Global Cancer Observatory. Cancer Tomorrow. https://gco.iarc.fr/tomorrow/en/dataviz/. Accessed 13 July 2022.
[v] Cerner Enviza CancerMPact® Patient Metrics 2022. CMP:CancerMPact®[Patient Metrics], Cerner Enviza. Available from www.cancermpact.com. Accessed 11 May 2023.
[vi] CancerMPact® [Treatment Architecture], Cerner Enviza. Available from www.cancermpact.com. Accessed 11 May 2023.
[vii] Cerner Enviza CancerMPact® [Treatment Architecture]. Available from www.cancermpact.com. Accessed 14 Apr 2023.
[viii] Halla K. Emerging Treatment Options for Advanced or Recurrent Endometrial Cancer. J Adv Pract Oncol. 2022 Jan;13(1):45-59. doi: 10.6004/jadpro.2022.13.1.4. Epub 2022 Feb 1. PMID: 35173988; PMCID: PMC8805805.
